| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 09/18/2003 | WO2003075891A1 Dispersed solid-containing complex carbohydrate |
| 09/18/2003 | WO2003075857A2 Amino-methyl substituted tetracycline compounds |
| 09/18/2003 | WO2003075847A2 NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS |
| 09/18/2003 | WO2003075845A2 Immunogenicity of glucan binding protein |
| 09/18/2003 | WO2003075836A2 Cathepsin cysteine protease inhibitors |
| 09/18/2003 | WO2003075741A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 09/18/2003 | WO2003075685A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 09/18/2003 | WO2003075676A1 Probiotic delivery system |
| 09/18/2003 | WO2003075670A1 Treatment and prevention of inflammatory disorders |
| 09/18/2003 | WO2003053915A3 Compounds for the treatment of inflammatory disorders |
| 09/18/2003 | WO2003053368A3 Chalcone derivatives and their use to treat diseases |
| 09/18/2003 | WO2003046135A3 Osteopontin-related compositions and methods |
| 09/18/2003 | WO2003045360A3 Use of gaba for the treatment of intestinal inflammations |
| 09/18/2003 | WO2003035007A3 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 09/18/2003 | WO2003024489A3 Combination of a nsaid and a pde-4 inhibitor |
| 09/18/2003 | WO2002083700B1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 09/18/2003 | WO2002080982A3 Nucleic acid mucosal immunization |
| 09/18/2003 | WO2002077174A3 Human cytokine receptor |
| 09/18/2003 | WO2002066646A3 Neurotransmission-associated proteins |
| 09/18/2003 | WO2002062750A9 Cannabinoid receptor ligands |
| 09/18/2003 | WO2002059308A3 Method of diagnosing and treating cartilage disorders |
| 09/18/2003 | WO2002036625A9 Prokineticin polypeptides, related compositions and methods |
| 09/18/2003 | US20030176686 Diagnosis, therapy; animal growth regulators; controlling cell differentiation; antiiinflammatory agents, antihistamines, Crohn's disease, anticancer agents, autoimmune disease |
| 09/18/2003 | US20030176650 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 09/18/2003 | US20030176498 Inhibitors of alpha4mediated cell adhesion |
| 09/18/2003 | US20030176491 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer |
| 09/18/2003 | US20030176487 For therapy and prophylaxis of disorders related to unregulated tyrosine kinase signal transduction, including cell proliferative and metabolic disorders |
| 09/18/2003 | US20030176479 Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| 09/18/2003 | US20030176475 For therapy of disorders of the gastrointestinal system, and of the central nervous system |
| 09/18/2003 | US20030176463 For therapy of disease states resulting from angiogenesis; can be administered orally |
| 09/18/2003 | US20030176455 Inhibiting cell death following cellular regeneration in a mammal in need thereof, which comprises providing with an effective amount of a rapamycin |
| 09/18/2003 | US20030176453 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 09/18/2003 | US20030176445 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 09/18/2003 | US20030176441 Inhibitsthe binding of eotaxin to the CCR-3 receptor and thereby provide a means of combating eosinophil induced diseases, such as asthma |
| 09/18/2003 | US20030176430 For therapy and prophylaxis of Tachykinin-mediated diseases |
| 09/18/2003 | US20030176429 2-thio-4h-3,1-benzoxazin-4-one derivatives for use as enzyme inhibitors |
| 09/18/2003 | US20030176416 For therapy of disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors |
| 09/18/2003 | US20030176413 Polycyclic guanine derivative phosphodiesterase V inhibitors |
| 09/18/2003 | US20030176405 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 09/18/2003 | US20030176401 Sodium salt of an azo derivative of 5-aminosalicylic acid |
| 09/18/2003 | US20030176394 Using an alginate having a molecular weight of more than 30, 000 and leas than 380,000 in the manufacture of pharmaceutical formulation for the inhibition of the proteolytic activity of pepsin and/or gastric juice in a mammal |
| 09/18/2003 | US20030176363 For therapy of T lymphocyte mediated inflammatory diseases in animals and man |
| 09/18/2003 | US20030176331 Having therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins; for therapy of cancer |
| 09/18/2003 | US20030176319 N4-acylcytosine-1,3- dioxolane nucleosides for treatment of viral infections |
| 09/18/2003 | US20030176317 Stabilization of hypoxia inducible factor (HIF) alpha |
| 09/18/2003 | US20030176315 Contacting latency-associated peptide- beta 1 (LAP- beta 1) or a functional variant thereof and integrin alpha v beta 3 or a functional variant thereof with test product under conditions that, in absence of test product, would permit interaction |
| 09/18/2003 | US20030175934 Controlling cell differentiation, cell proliferation; anticancer agents |
| 09/18/2003 | US20030175920 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 09/18/2003 | US20030175881 Nucleic acids encoding (poly) peptides having chips activity |
| 09/18/2003 | US20030175855 Human sdf-5 protein and compositions |
| 09/18/2003 | US20030175775 Ligand for G-protein coupled receptor GPR43 and uses thereof |
| 09/18/2003 | US20030175680 Methods of treating and preventing bone loss |
| 09/18/2003 | US20030175374 Oxidation resistance; anticancer agents, antiinflammatory agents; sunscreen agents |
| 09/18/2003 | US20030175370 Dry mixture of carbohydrates and drugs; wound healing agents |
| 09/18/2003 | US20030175363 Pharmaceutical composition and process for isolation of trans-tetracos-15-enoic acid and method of treatment for hepatotoxicity |
| 09/18/2003 | US20030175360 Comprising locally acting anesthetic, and an antacid; treatment of gastroesophageal reflux disease |
| 09/18/2003 | US20030175334 Phospholipid bodies and use thereof in medical treatment |
| 09/18/2003 | US20030175296 Chimaeric hepadnavirus core antigen proteins |
| 09/18/2003 | US20030175274 Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agents |
| 09/18/2003 | US20030175269 Light and heavy chain peptides, used as antagonists of CD antigen or membrane proteins, for prophylaxis of autoimmune diseases |
| 09/18/2003 | US20030175215 A beverage for prevention of tooth damage by plaque acid production; a carbohydrate drink or candy comprising maltodextrin and less than 1.0% of mono- and di-saccharides |
| 09/18/2003 | US20030175209 Image diagnosis of a brain tumor, renal carcinoma; tumor treatment therapies, immunotherapy |
| 09/18/2003 | CA2482191A1 Spiro compounds with npy antagonistic activity |
| 09/18/2003 | CA2480962A1 Immunogenicity of glucan binding protein |
| 09/18/2003 | CA2479065A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 09/18/2003 | CA2478942A1 An optically active pyridine derivative and a medicament containing the same |
| 09/18/2003 | CA2478921A1 Novel chalcone derivatives and uses thereof |
| 09/18/2003 | CA2478706A1 Oxo-azabicyclic compounds |
| 09/18/2003 | CA2478701A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity |
| 09/18/2003 | CA2478684A1 Dispersed solid-containing complex carbohydrate |
| 09/18/2003 | CA2478652A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 09/18/2003 | CA2478599A1 Salts of nateglinide |
| 09/18/2003 | CA2478522A1 Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis |
| 09/18/2003 | CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| 09/18/2003 | CA2478245A1 Treatment and prevention of inflammatory disorders |
| 09/18/2003 | CA2478065A1 Macrocyclic compounds useful as pharmaceuticals |
| 09/18/2003 | CA2474771A1 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| 09/17/2003 | EP1344823A1 Novel g protein-coupled receptor proteins and dnas thereof |
| 09/17/2003 | EP1344779A1 Azolo-pyrimidines |
| 09/17/2003 | EP1344524A1 Reflux inhibitors |
| 09/17/2003 | EP1344458A1 Probiotic delivery system |
| 09/17/2003 | EP1343876A2 Modulators of activity of g-protein-coupled receptor kinases |
| 09/17/2003 | EP1343819A1 Hla-a2.1 binding peptides and their uses |
| 09/17/2003 | EP1343818A1 Modified tachykinin receptors |
| 09/17/2003 | EP1343803A2 2-substituted estrogens as antiangiogenic agents |
| 09/17/2003 | EP1343791A2 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
| 09/17/2003 | EP1343786A1 Novel pyridine-substituted pyrazolopyridine derivatives |
| 09/17/2003 | EP1343784A2 Urea substituted imidazoquinoline ethers |
| 09/17/2003 | EP1343781A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 09/17/2003 | EP1343778A2 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists |
| 09/17/2003 | EP1343775A2 Piperazine derivatives |
| 09/17/2003 | EP1343769A1 Benzoylpyridazines |
| 09/17/2003 | EP1343768A1 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 09/17/2003 | EP1343764A1 Urea and urethane derivatives as integrin inhibitors |
| 09/17/2003 | EP1343759A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 09/17/2003 | EP1343757A1 Indole derivatives |
| 09/17/2003 | EP1343751A2 Cyclic derivatives as modulators of chemokine receptor activity |
| 09/17/2003 | EP1343561A1 Serine protease inhibitors |
| 09/17/2003 | EP1343529A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| 09/17/2003 | EP1343520A2 New therapeutic uses of smr1 peptides |